logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ELCC 2018 — QoL data support alectinib as first-line SOC in ALK+ NSCLC

Time to symptom deterioration was 20 weeks longer with alectinib vs crizotinib.